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Cutting Edge: The NLRP3 Inflammasome Links
Complement-Mediated Inflammation and IL-1b Release
Federica Laudisi,* Roberto Spreafico,* Maximilien Evrard,* Timothy R. Hughes,†
Barbara Mandriani,* Matheswaran Kandasamy,‡ B. Paul Morgan,†
Baalasubramanian Sivasankar,‡ and Alessandra Mortellaro*
The complement system is a potent component of the
innate immune response, promoting inflammation and
orchestrating defense against pathogens. However, dys-
regulation of complement is critical to several autoim-
mune and inflammatory syndromes. Elevated expression
of the proinflammatory cytokine IL-1b is often linked
to such diseases. In this study, we reveal the mechanistic
link between complement and IL-1b secretion using mu-
rine dendritic cells. IL-1b secretion occurs following in-
tracellular caspase-1 activation by inflammasomes. We
show that complement elicits secretion of both IL-1b
and IL-18 in vitro and in vivo via the NLRP3 inflam-
masome. This effect depends on the inflammasome
components NLRP3 and ASC, as well as caspase-1 ac-
tivity. Interestingly, sublethal complement membrane
attack complex formation, but not the anaphylatoxins
C3a and C5a, activated the NLRP3 inflammasome
in vivo. These findings provide insight into the molecu-
lar processes underlying complement-mediated inflam-
mation and highlight the possibility of targeting IL-1b
to control complement-induced disease and pathologi-
cal inflammation. The Journal of Immunology, 2013,
191: 1006–1010.
I
nflammation is an integrated immune process that is
rapidly initiated either when tissues are damaged or
by pathogenic infections. Two main players of the in-
flammatory process are the complement system and innate
phagocytes (macrophages and dendritic cells [DCs]). Com-
plement is a large collection of plasma proteins whose acti-
vation culminates in the assembly and deposition of membrane
attack complexes (MACs) that kill infected or damaged cells
through disrupting membrane integrity. Nonlethal amounts of
MAC induce profound phagocyte activation, with the pro-
duction of inflammatory mediators, such as PGs, leukotrienes,
and reactive oxygen species (1). Alongside MAC formation,
the production of bioactive complement fragments C3a and
C5a, known as anaphylatoxins, promotes local inflammatory
events, including recruitment of phagocytic cells to the site of
inflammation (2). These phagocytes cooperate with comple-
ment, binding and internalizing the infectious agents via cell
surface receptors (TLRs, lectins, complement and Fc recep-
tors) and releasing proinflammatory cytokines (IL-1, TNF-a,
and IL-6). Although inflammation is crucial for effective res-
olution of infection, it also has the capacity to damage cells
and tissue if inappropriately regulated. Unrestrained activa-
tion generates a harmful chronic inflammatory environment
that can result in conditions such as rheumatoid arthritis, lupus,
multiple sclerosis, and Alzheimer’s disease (3). As such, there
is a pressing need to understand the complex process of in-
flammation and to identify new targets for therapeutic inter-
vention in the treatment of autoimmune and autoinflammatory
disorders.
The complement system itself has recently begun to attract
interest as a therapeutic target. In particular, it seems that
complement components can enhance proinflammatory TLR-
mediated signaling in phagocytes, leading to increased pro-
duction of IL-1b (4, 5). IL-1b is critically involved in several
inflammatory diseases and is elevated in many conditions
characterized by complement overactivation (4, 5). However,
it is unknown whether, or how, complement and IL-1b are
linked.
One possibility is that the interaction of complement system
with TLRs on phagocytes also enhances TLR cross-talk with
members of the intracellular nucleotide-binding oligomeri-
zation domain-like receptor family. Some nucleotide-binding
oligomerization domain-like receptors assemble with the
adaptor protein ASC to form the caspase-1–activating com-
plexes, which are responsible for the production of active
IL-1b. Activation of the NLRP3 inflammasome promotes
maturation of the proinflammatory cytokines IL-1b and
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IL-18 (6). Thus, IL-1b production occurs in two steps: pro–
IL-1b synthesis is triggered by pattern recognition receptor
ligation, leading to NF-kB activation, before being cleaved by
inflammasome-activated caspase-1 to produce the active cy-
tokine (7). The NLRP3 inflammasome is activated by diverse
stimuli, including microbial molecules, host-derived mole-
cules associated with stress or danger, and crystalline or par-
ticulate substances (8, 9); many of these are also able to induce
complement activation.
Thus, we hypothesized that complement and IL-1b were
linked through activation of the inflammasome. In this study,
we show that complement induces IL-1b and IL-18 matu-
ration and release from DCs, dependent on the NLRP3
inflammasome. MAC deposition at sublethal levels, but not
C3a or C5a, activated the NLRP3 inflammasome in vivo.
Thus, our results reveal a new molecular mechanism linking
complement with proinflammatory cytokine production from
immune phagocytes. This brings a new perspective to the
search for therapeutic targets in diseases characterized by ab-
normal complement and IL-1b activity.
Materials and Methods
Mice
C57BL/6 (B6) and BALB/c mice were purchased from the Biological Resource
Center (Agency for Science, Technology, and Research), and C3ar2/2 and
C5ar2/2 mice on the BALB/c background were from The Jackson Labora-
tory. Nlrp32/2, Asc-/-, and C6-/- (B6 background) mice were described pre-
viously (10–12). All mice were backcrossed onto the B6 or BALB/c
background for at least eight generations. Experiments were conducted with
8–10-wk old female mice bred under specific pathogen–free conditions, un-
der the approval of the local ethics committee.
Cell culture and stimulation
Bone marrow DCs, prepared as described (13), were primed with ultrapure
LPS (0.1 mg/ml, Escherichia coli 055:B5; Alexis) in Opti-MEM medium (Life
Technologies) for 3 h. Medium was replaced by adding normal baby rabbit
serum as a source of complement (Cedarlane Laboratories) or monosodium
urate (MSU; 250 mg/ml; Alexis) for 4 h. In some experiments, cells were
preincubated with the caspase-1 inhibitor Z-YVAD-FMK after LPS priming.
To inhibit MAC formation, normal rabbit complement (NRC) was pre-
incubated with anti-C6 mAb (1.25 mg/ml, clone WU 6-4; Hycult), alone or
with anti-C9 mAb (7.5 ng/ml), for 30 min at 37˚C before adding to DCs.
ELISA
Murine IL-1b, IL-1a, and IL-6 were measured in cell-free supernatants and
sera using a DuoSet ELISA kit (R&D Systems), according to the manu-
facturer’s instructions. IL-18 was measured by ELISA, as described (13).
MAC deposition
DCs were stimulated with LPS in combination with NRC or heat-inactivated
(HI)-NRC for 4 h. Cells were collected and washed, and FcgII/FcgIIIRs were
blocked by anti-mouse CD16/32 (clone 93; eBioscience). Anti-human C9 Ab
and anti-mouse IgG1 were then used to detect MAC formation on cell
membrane. Single events were acquired using a BD LSR II flow cytometer
(BD Biosciences) and analyzed by FlowJo software (TreeStar).
Immunoblot analysis
Supernatants were immunoprecipitated with anti-mouse IL-1b Ab (clone
B122; BioLegend), followed by Protein G Sepharose beads (GE Healthcare),
according to the manufacturer’s instructions. Protein pellets were resuspended
in sample loading buffer and resolved by 15% SDS-PAGE. Immunoblotting
of cell lysates was performed following standard procedures. Membranes were
immunoblotted with goat anti-mouse IL-1b or anti-mouse caspase-1 p10 Ab
(clone M-20; Santa Cruz Biotechnology).
In vivo complement activation
Mice were injected i.p. with 20 mg/kg LPS (E. coli 0111:B4; Sigma). Where
indicated, mice also received 60 mg cobra venom factor (CVF; Quidel) i.p.
After 3 h, mice were sacrificed, and blood was collected. IL-1b, IL-6, and IL-
18 levels in sera were measured by ELISA.
Statistical analysis
The data shown in each figure represent the mean of three or more independent
experiments. Error bars indicate SD or SEM, as indicated. Data were analyzed
using Prism 5 software (GraphPad), and statistical significance was determined
by an unpaired two-tailed Student t test, or multiple test corrections when
testing more than two conditions.
Results and Discussion
Complement induces IL-1b maturation and caspase-1 processing
We first asked whether complement could induce the release
of mature IL-1b from phagocytes. Murine bone marrow–
derived DCs in serum-free media were primed with LPS to
induce pro–IL-1b production. Cells were then washed and
treated with NRC at different concentrations (Fig. 1A).
Complement or LPS alone induced barely detectable amounts
of IL-1b secretion; however, when combined, IL-1b was
produced in a dose- and time-dependent manner (Fig. 1A,
Supplemental Fig. 1). IL-1a was also released by LPS and
complement–treated DCs. The levels of IL-1b and IL-1a
released upon NRC treatment were comparable to those from
DCs treated with MSU crystals, a classical NLRP3 inflam-
masome activator (Fig. 1A, Supplemental Fig. 1). Heat-
inactivated NRC (HI-NRC) was included as a control; it
induced barely detectable IL-1b and IL-1a production, in-
dicating that complement activation was the genuine trigger
for IL-1 release. IL-6 production by LPS-primed DCs in
response to NRC or HI-NRC was similar, confirming that
FIGURE 1. LPS-primed DCs treated with NRC rapidly release IL-1b and
process caspase-1. (A) ELISA of IL-1b and IL-1a in cell-free supernatants from
LPS-primed DCs treated with different concentrations (1.25, 2.5, 5%) of NRC
or HI-NRC. Cytokines released by LPS-primed DCs treated with MSU
(250 mg/ml) were included. Data represent mean 6 SD for at least three in-
dependent experiments. (B) Immunoblot detection of mature IL-1b p17 in cell-
free supernatant from LPS-primed DCs stimulated with NRC or HI-NRC (5
and 2.5%) or MSU. Levels of pro–IL-1b were also assessed in total cell lysates;
a-tubulin was used as loading control. (C) Caspase-1 activation was detected by
immunoblot in DCs activated with NRC (2.5%), HI-NRC, or MSU. (D)
Lactate dehydrogenase analysis was performed to determine cell viability after
DCs were stimulated with different concentrations of NRC (2.5, 5, 10%) or
HI-NRC (10%). Data shown are representative of three independent experi-
ments. *p , 0.05, **p , 0.01, ***p , 0.001. ns, Not significant.
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NRC does not influence DCs’ ability to respond to LPS stim-
ulation (data not shown).
IL-1b secretion was further confirmed by immunoblot
of cell supernatants, which detected active IL-1b p17 only
in samples from LPS-primed DCs stimulated with NRC or
MSU but not with HI-NRC (Fig. 1B). Complement-induced
IL-1b maturation was associated with activation of caspase-1
cleavage, measured by immunoblot of caspase-1 p10 in cell-
free supernatants (Fig. 1C).
When we measured cell death, using lactate dehydrogenase
release by complement-treated DCs, we noticed that it was
proportional to complement dose, as expected (Fig. 1D).
However, at a complement concentration of 2.5%, we did not
observe a significant increase in cell death over background
(Fig. 1D), yet IL-1b release was consistent at this concen-
tration (Fig. 1A), indicating that IL-1b secretion was not
merely triggered by cell necrosis (14). Therefore, we selected
the sublethal complement concentration of 2.5% to investi-
gate the molecular mechanism underlying complement-me-
diated caspase-1 activation in subsequent experiments.
The NLRP3 inflammasome is required for complement-induced
caspase-1 activation and IL-1b release
To determine whether the NLRP3 inflammasome is crucial for
IL-1b production in response to complement, we stimulated
LPS-primed DCs from wild-type (WT), Nlrp32/2, and Asc2/2
mice with a sublethal complement dose, as above. WT DCs
secreted readily detectable amounts of mature IL-1b and IL-
18 (Fig. 2A), whereas DCs deficient for Nlrp3 or Asc did not,
confirming the role of the NLRP3 inflammasome. Nlrp32/2
and Asc2/2 DCs produced IL-6 amounts similar to WT DCs,
indicating that their functionality was not affected by treat-
ment (Fig. 2A). In Nlrp32/2 and Asc2/2 cells, cleaved IL-1b
p17 was completely absent after complement exposure (Fig.
2B). Similarly, the caspase-1 inhibitor Z-YVAD abrogated
maturation and release of IL-1b in DCs treated with com-
plement (Fig. 2C, 2D). Complement-mediated activation of
NLRP3 inflammasome was dependent on K+ and Ca2+ fluxes
(Supplemental Fig. 2). Indeed, blockade of K+ efflux or Ca2+
influx suppressed the release of IL-1b by DCs after comple-
ment stimulation (Supplemental Fig. 2).
We further evaluated the role of the NLRP3 inflammasome
in complement-mediated IL-1b and IL-18 production in
vivo. We evoked complement activation in mice by i.p. ad-
ministration of LPS (15). Serum IL-1b and IL-18 levels 3 h
after LPS treatment were significantly higher than were those
in untreated mice. Notably, serum IL-1b and IL-18 were
markedly decreased in Nlrp32/2 and Asc2/2 mice (Fig. 2E).
In addition, we caused enhanced complement activation
in vivo by administration of LPS with CVF, which causes
FIGURE 2. IL-1b release induced by complement is NLRP3 dependent. (A) IL-1b, IL-18, and IL-6 levels in supernatants of LPS-primed WT, Nlrp32/2, and
Asc2/2 DCs treated with NRC (2.5%) or MSU (250 mg/ml) for 4 h. Data represent mean 6 SD for at least three independent experiments. (B) Mature IL-1b
p17 and pro–IL-1b were detected in precipitated supernatants and cell lysates, respectively, from WT, Nlrp32/,2 and Asc2/2 DCs by immunoblot. Data shown
are representative of three independent experiments. (C and D) IL-1b released by WT LPS-primed DCs pretreated with the caspase-1 inhibitor Z-YVAD (10 and
20 mM) for 1 h and then stimulated with NRC or MSU for 4 h. ELISA (C) and immunoblot (D) were performed to detect mature IL-1b p17, intracellular pro–
IL-1b, and a-tubulin. (E) Serum cytokine levels of WT, Nlrp32/2, and Asc2/2 mice receiving i.p. injections of LPS alone or with CVF (60 mg/mouse). *p ,
0.05, **p , 0.01, ***p , 0.001.
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systemic hyperactivation of complement. LPS/CVF coad-
ministration boosted serum IL-1b and IL-18 levels in WT
mice but not in mice deficient for Nlrp3 or Asc (Fig. 2E).
These data corroborate the results obtained using LPS alone.
Serum IL-6 levels in response to LPS/CVF remained unal-
tered. Collectively, these data indicate that IL-1b and IL-18
secretion induced by complement involves the NLRP3/ASC/
caspase-1 pathway in vitro and in vivo.
Sublethal MAC formation regulates NLRP3 inflammasome activation
We went on to identify the mechanisms involved in NLRP3
inflammasome activation by complement in vivo, beginning
with the possible role of C3a and C5a anaphylatoxins. Serum
IL-1b and IL-6 levels were similar in WT, C3ar2/2, C5ar2/2,
and C3ar2/2C5ar2/2 mice after complement activation in-
duced by LPS, indicating that anaphylatoxins play no major
role in NLRP3 inflammasome induction by complement
(Fig. 3A). However, the NLRP3 inflammasome can also be
activated through pore-forming toxins, leading us to wonder
whether the complement system’s pore-forming complex
(MAC) might be involved (10). MAC formation was sup-
pressed by incubating NRC with an anti–C6-neutralizing Ab
before incubation with DCs. This significantly reduced both
the percentage and the mean fluorescence intensity of cells
positive for C9 (Fig. 3B, data not shown). IL-1b and IL-1a,
but not IL-6, release was significantly inhibited by treatment
with anti-C6 Ab, alone or in combination with an anti-C9 Ab
(Fig. 3C, data not shown). Blocking MAC formation also
markedly suppressed IL-1b p17 maturation, as visualized by
immunoblot (Fig. 3D).
We evaluated the role of MAC in vivo using C62/2 mice in
which MAC deposition is impaired. The complement cascade
was triggered in WT and C62/2 mice by i.p. LPS injections.
In mice lacking C6, serum IL-1b was significantly reduced
compared with WT littermates, whereas IL-6 levels remained
unchanged (Fig. 3E). Collectively, these data indicate that the
MAC is indispensable for NLRP3 inflammasome-mediated
IL-1b maturation.
In this study, we defined a new mechanism triggered by
complement to promote inflammation. We provide clear ev-
idence that sublethal MAC formation activates the NLRP3
inflammasome to enable caspase-1 processing and maturation
of IL-1b and IL-18.
MAC has been implicated in the pathology of chronic in-
flammatory disorders and diseases, including atherosclerosis,
reperfusion injury, and glomerular damage (16, 17). Moreover,
deficiency in decay accelerating factor, a negative regulator of
both the classical and alternative pathways of complement
activation, increases complement activation, which results in
higher LPS-induced IL-1b production in vivo (5).
Inhibition of MAC formation may provide a therapeutic
approach for the treatment of chronic inflammatory diseases,
not only by preventing cell lysis and tissue damage, but also by
reducing IL-1b release and inflammation. Prevention of C5
activation through administration of an anti-mouse C5 Ab
abrogated inflammation in complement factor (Cf) H2/2
mice that were developing spontaneous membranoprolifer-
ative glomerulonephritis (18). Ongoing phase II clinical trials
of Soliris (eculizumab), a fully humanized anti-C5 Ab for the
treatment of atypical hemolytic uremic syndrome, which is
associated with mutations in Cf H, have achieved remarkable
results (19). Moreover, eculizumab can also limit glomerular
inflammation in a subset of patients with the most inflam-
matory forms of C3 glomerulonephritis, which is accompa-
nied by circulating MAC (20). It would be interesting to
measure serum IL-1b levels in atypical hemolytic uremic
syndrome/C3 glomerulonephritis patients to understand
whether neutralization of C5, which blocks both C5a and
C5b, critical components for MAC deposition, could also
normalize serum IL-1b levels. Another productive approach
might be to combine eculizumab with IL-1b blockers, such as
anakinra and the anti-human IL-1b Ab (canakinumab, Ilaris),
or to target C6 or C9 directly. IL-1b neutralization by
anakinra successfully decreased C3 deposition, MAC forma-
tion, and IL-1 in the brains of two patients with acute
hemorrhagic leukoencephalitis, a rare demyelinating disorder
associated with partial Cf I deficiency. Based on the known
clinical facts and the findings shown in this study, IL-1b
FIGURE 3. Sublethal MAC deposition activates NLRP3 inflammasome
and IL-1bmaturation. (A) IL-1b and IL-6 levels in serum fromWT mice and
mice deficient in C3ar, C5ar, or C3ar, and C5ar, receiving LPS injections i.p.
Data represent mean 6 SEM of five to six mice/group. (B) MAC deposition
measured by C9+ cells was assessed by flow cytometry of DCs treated with
HI-NRC or NRC after preincubation with anti-C6 Ab or isotype control for
4 h. Data represent mean percentage 6 SEM for at least four independent
experiments. (C) IL-1b and IL-1a release was assessed in supernatants from
LPS-primed DCs treated with NRC (1.25%) in the presence of anti-C6 Ab
(1.25 mg/ml), alone or with an anti-C9 Ab (7.5 ng/ml). Treatment with NRC
together with isotype controls is also shown. (D) Mature IL-1b p17 released
by LPS-primed DCs after NRC treatment was detected in precipitated
supernatants by immunoblot. Intracellular pro–IL-1b and a-tubulin were
also analyzed in cell lysates. (E) Serum IL-1b and IL-6 levels from WT and
C62/2 mice injected i.p. with LPS (20 mg/kg). *p , 0.05, **p , 0.01, ***p ,
0.001. ns, Not significant.
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modulators should be investigated as an adjunct therapy for the
management of diseases caused by complement dysregulation.
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